AMPK acts as a new target for the treatment of type 2 diabetes

Bin GE,Mei-lin XIE,Zhen-lun GU,Wen-xuan ZHOU,Ci-yi GUO
DOI: https://doi.org/10.3321/j.issn:1001-1978.2008.05.006
2008-01-01
Abstract:Type 2 diabetes is characterized by the abnormal metabolism of glucose and lipid, due in part to insulin resistance in peripheral tissues. The AMP activated protein kinase (AMPK) is a heterotrimeric protein consisting of α catalytic subunit and β/γ regulatory subunits. It acts as a master switch in regulating balance of the energy metabolism. In the muscle and liver, the activated AMPK enhances glucose uptake, fatty acid oxidation and insulin sensitivity, and decreases production of glucose, cholesterol, and triglycerides. The recent finding suggests that the leading anti-diabetic drugs metformin and rosiglitazone regulate glucose metabolism partially through AMPK. These data suggest that AMPK is the potential pharmacological target for the treatment of type 2 diabetes.
What problem does this paper attempt to address?